DOI QR코드

DOI QR Code

Clinical Observation on Recombinant Human Endostatin Combined with Chemotherapy for Advanced Gastrointestinal Cancer

  • Gao, Shao-Rong (The Third Department of Chemotherapy, Weihai Municipal Hospital) ;
  • Li, Lu-Ming (Internal Medicine, Weihai Municipal Hospital) ;
  • Xia, Hai-Ping (The First Department of Surgery, 404 Hospital of the Chinese People's Liberation Army) ;
  • Wang, Guang-Ming (Pharmacy Department, Weihai Municipal Hospital) ;
  • Xu, Hong-Yan (The Third Department of Chemotherapy, Weihai Municipal Hospital) ;
  • Wang, Ai-Rong (The Third Department of Chemotherapy, Weihai Municipal Hospital)
  • Published : 2015.05.18

Abstract

Objective: To explore the clinical efficacy and toxic and side effects of recombinant human endostatin (rhendostatin/endostar) combined with chemotherapy in the treatment of advanced gastric cancer. Materials and Methods: A total of 70 patients with advanced gastrointestinal adenocarcioma confirmed by histopathology and/or cytological examination were divided into group A (37 patients) and group B (33 patients). Patients in group A were given intravenous drip of 15 mg endostar added into 500 mL normal saline, once every other day until the cessation of chemotherapy or patients' maximal tolerance to chemotherapy. Patients in group B received chemotherapy alone. Two groups selected the same chemotherapy regimens. FOLFIRI scheme: 90-min intravenous drip of $180mg/m^2$ irinotecan, intravenous drip of $200mg/m^2$ calcium folinate (CF) and $400mg/m^2$ 5-fluorouracil (5-Fu) on d1, and continuous intravenous pumping of 2 $400mg/m^2$ 5-Fu for 46 h. FOLFOX4 scheme: intravenous injection of $85mg/m^2$ oxaliplatin (L-OHP), $200mg/m^2$ calcium folinate (CF) and $400mg/m^2$ 5-FU on d1 for 2 h, and then continuous intravenous pumping of 2 $400mg/m^2$ 5-Fu for 46 h. XELOX scheme: oral administration of 1 $500mg/m^2$ xeloda (or tegafur 50~60 mg) in twice during d1~14 and intravenous drip of $135mg/m^2$ L-OHP on d1 for 2 h. The modified FOLFOX scheme: intravenous injection of $135mg/m^2$ L-OHP on d1 for 2 h, $200mg/m^2$ CF and 1.0 g tegafur during d1~5. Whereas, control Group B received chemotherapy regimens which were same as Group A, but no addition of endostar. Before chemotherapy, patients were given intravenous injection of 8 mg ondansetron, intramuscular injection of 10 mg metoclopramide and 20 mg diphenhydramine for prevention of vomiting, protection of liver and stomach as well as symptomatic supportive treatment. One cycle was 21 d, 4~6 cycles in total. The efficacy was evaluated every 2 cycles. Results: 32 patients in Group A could be evaluated, and the response rate (RR) and disease control rate (DCR) were 59.38% and 78.13%, respectively. 31 patients in Groups could be evaluated, and the RR and DCR were 32.26% and 54.84%, respectively. The differences between 2 groups were significant. The toxic effects include myelosuppression, gastrointestinal reaction, fatigue, cardiotoxicity and peripheral neurotoxicity. Conclusions: Preliminary observations show that endostar (once every other day) combined with chemotherapy is effective in the treatment of advanced gastrointestinal cancer, with low toxic effects, good tolerance, deserving further study.

Keywords

Recombinant human endostatin/endostar;gastrointestinal cancer;targeted therapy;chemotherapy

References

  1. Chen G, Shen ZL, Wang L, et al (2013). Hsa-miR-181a-5p expression and effects on cell proliferation in gastric cancer. Asian Pac J Cancer Prev, 14, 3871-5. https://doi.org/10.7314/APJCP.2013.14.6.3871
  2. Chen YX, Qin SK, Liu XF, et al (2009). Clinical study of rh-endostatin combined with chemotherapy for advanced gastric cancer. Chin Clin Oncol, 14, 327-31.
  3. FolkmanJ, MerlerE, AbernathyC, etal. Isolated of a tumor factor responsible for anfiogesis. J Exp Med, 1971, 133, 275-88. https://doi.org/10.1084/jem.133.2.275
  4. Ge W, Cao DD, Wang HM, et al (2011). Endostar Combined with Chemotherapy versus Chemotherapy alone for Advanced NSCLCs: A Meta-analysis. Asian Pac J Cancer Prev, 12, 2901-7.
  5. Kirschm, Schackert G, Black PM (2004). Metastasis and angiogenesis. Cancer Treat Res, 117, 285. https://doi.org/10.1007/978-1-4419-8871-3_17
  6. Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. https://doi.org/10.7314/APJCP.2014.15.16.6587
  7. O'Reilly MS, Boehm T, Shing Y (1997). Endostain: an endogenous inhibitor of angiofenesis and tumor growth. Cell, 88, 277-85. https://doi.org/10.1016/S0092-8674(00)81848-6
  8. Sun Y, Shi YK (2007). Manual of Clinical Oncology. People's Medical Publishing House, 492-6, 817-9.
  9. Shao Mingwen, Qiu Jinrong, Wu Hao, et al (2014). Mechanism of Shenyi Capsule Concomitant with Endostar and Chemotherapy on the Growth and Apoptosis of MCF-7 Breast Cancer Cells. J Int Transl Med, 2, 299-302.
  10. Wang JW, Sun Y, Liu YY, et al (2005). Results of randomized, multicenter, double blind phase III trial of rh-endostatin (YH16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer, 8, 283-90.
  11. Li Y, Huang XE, Yan PW, et al (2010). Efficacy and Safety of Endostar Combined with Chemotherapy in Patients with Advanced Solid Tumors. Asian Pac J Cancer Prev, 11, 1119-23.
  12. Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
  13. Xu X, Wang L, Xu HQ, et al (2013). Clinical comparison between paclitaxel liposome (Lipusu$^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 4, 2591-4.

Cited by

  1. Effect of protein adsorption on cell uptake and blood clearance of methoxy poly(ethylene glycol)-poly(caprolactone) nanoparticles vol.133, pp.3, 2015, https://doi.org/10.1002/app.42884
  2. Anticancer effect of cucurbitacin B on MKN-45 cells via inhibition of the JAK2/STAT3 signaling pathway vol.12, pp.4, 2016, https://doi.org/10.3892/etm.2016.3670
  3. Recent drug therapies for corneal neovascularization vol.90, pp.5, 2017, https://doi.org/10.1111/cbdd.13018
  4. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01) vol.142, pp.10, 2017, https://doi.org/10.1002/ijc.31217
  5. Clinical observation of recombinant human endostatin in treating relapsed refractory multiple myeloma vol.45, pp.12, 2018, https://doi.org/10.1111/1440-1681.13016